Nomura upgrades Fortis Healthcare to "buy" from "neutral", but cuts its target price to Rs 124 from Rs 170, citing recent underperformance and improvement in return ratios.
"Near-term ROE (Return on equity) is low at 1-3 percent but we expect average incremental ROE over the next five years to be 33 percent," said Nomura in a report.
The investment bank adds that in its view Fortis has come to the end of an investment cycle and will now focus on cash flows and profitability.
Anda sedang membaca artikel tentang
Nomura upgrades Fortis Healthcare to 'buy'
Dengan url
https://kesehatanda.blogspot.com/2013/05/nomura-upgrades-fortis-healthcare-to-buy.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Nomura upgrades Fortis Healthcare to 'buy'
namun jangan lupa untuk meletakkan link
Nomura upgrades Fortis Healthcare to 'buy'
sebagai sumbernya
0 komentar:
Posting Komentar